Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.29
HZNP's Cash-to-Debt is ranked lower than
76% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. HZNP: 0.29 )
Ranked among companies with meaningful Cash-to-Debt only.
HZNP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.72 Max: 2.56
Current: 0.29
0.07
2.56
Equity-to-Asset 0.25
HZNP's Equity-to-Asset is ranked lower than
90% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. HZNP: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
HZNP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.44 Max: 0.7
Current: 0.25
-0.77
0.7
Debt-to-Equity 1.84
HZNP's Debt-to-Equity is ranked lower than
92% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. HZNP: 1.84 )
Ranked among companies with meaningful Debt-to-Equity only.
HZNP' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.51  Med: 0.63 Max: 1.84
Current: 1.84
-2.51
1.84
Piotroski F-Score: 4
Altman Z-Score: 0.02
Beneish M-Score: -3.04
WACC vs ROIC
2.94%
-15.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -42.98
HZNP's Operating Margin % is ranked lower than
80% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. HZNP: -42.98 )
Ranked among companies with meaningful Operating Margin % only.
HZNP' s Operating Margin % Range Over the Past 10 Years
Min: -1841.5  Med: -57.9 Max: 7.31
Current: -42.98
-1841.5
7.31
Net Margin % -42.40
HZNP's Net Margin % is ranked lower than
80% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. HZNP: -42.40 )
Ranked among companies with meaningful Net Margin % only.
HZNP' s Net Margin % Range Over the Past 10 Years
Min: -1635.12  Med: -201.31 Max: 5.22
Current: -42.4
-1635.12
5.22
ROE % -35.21
HZNP's ROE % is ranked lower than
79% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. HZNP: -35.21 )
Ranked among companies with meaningful ROE % only.
HZNP' s ROE % Range Over the Past 10 Years
Min: -523.78  Med: -107.35 Max: 4.27
Current: -35.21
-523.78
4.27
ROA % -11.24
HZNP's ROA % is ranked lower than
75% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. HZNP: -11.24 )
Ranked among companies with meaningful ROA % only.
HZNP' s ROA % Range Over the Past 10 Years
Min: -186.55  Med: -59.51 Max: 1.89
Current: -11.24
-186.55
1.89
ROC (Joel Greenblatt) % -1014.92
HZNP's ROC (Joel Greenblatt) % is ranked lower than
89% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. HZNP: -1014.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HZNP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7948.82  Med: -2263.21 Max: 520.88
Current: -1014.92
-7948.82
520.88
3-Year Revenue Growth Rate 73.80
HZNP's 3-Year Revenue Growth Rate is ranked higher than
97% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. HZNP: 73.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HZNP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26 Max: 115.5
Current: 73.8
0
115.5
3-Year EPS without NRI Growth Rate -23.70
HZNP's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. HZNP: -23.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
HZNP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -52 Max: -23.7
Current: -23.7
GuruFocus has detected 3 Warning Signs with Horizon Pharma PLC $HZNP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HZNP's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

HZNP Guru Trades in Q3 2016

Ken Heebner 1,000,000 sh (New)
Paul Tudor Jones 49,605 sh (New)
Steven Cohen 509,400 sh (+41.58%)
Julian Robertson 673,933 sh (-24.66%)
» More
Q4 2016

HZNP Guru Trades in Q4 2016

Joel Greenblatt 126,466 sh (New)
Paul Tudor Jones 104,075 sh (+109.81%)
Ken Heebner 1,530,000 sh (+53.00%)
Julian Robertson 793,933 sh (+17.81%)
Steven Cohen 572,900 sh (+12.47%)
» More
Q1 2017

HZNP Guru Trades in Q1 2017

Julian Robertson Sold Out
Ken Heebner Sold Out
Steven Cohen 427,200 sh (-25.43%)
Joel Greenblatt 37,797 sh (-70.11%)
Paul Tudor Jones 20,100 sh (-80.69%)
» More
Q2 2017

HZNP Guru Trades in Q2 2017

John Paulson 4,935,500 sh (New)
Jim Simons 107,900 sh (New)
Steven Cohen 3,653,500 sh (+755.22%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 New Buy0.8%$9.65 - $15.75 $ 12.32-1%4,935,500
Joel Greenblatt 2017-06-30 Sold Out 0.01%$9.65 - $15.75 $ 12.32-1%0
Joel Greenblatt 2017-03-31 Reduce -70.11%0.02%$14.37 - $18.09 $ 12.32-24%37,797
Julian Robertson 2017-03-31 Sold Out 2.33%$14.37 - $18.09 $ 12.32-24%0
Ken Heebner 2017-03-31 Sold Out 1.1%$14.37 - $18.09 $ 12.32-24%0
Ken Heebner 2016-12-31 Add 53.00%0.38%$14.55 - $21.7 $ 12.32-32%1,530,000
Julian Robertson 2016-12-31 Add 17.81%0.35%$14.55 - $21.7 $ 12.32-32%793,933
Joel Greenblatt 2016-12-31 New Buy0.03%$14.55 - $21.7 $ 12.32-32%126,466
Ken Heebner 2016-09-30 New Buy0.86%$16.72 - $23.19 $ 12.32-37%1,000,000
Julian Robertson 2016-09-30 Reduce -24.66%1.17%$16.72 - $23.19 $ 12.32-37%673,933
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:ENDP, NAS:INNL, NYSE:PRGO, NYSE:AGN » details
Traded in other countries:HPR.Germany,
Headquarter Location:Ireland
Horizon Pharma PLC is a pharmaceutical company. The company focuses on identifying, developing, and commercializing of differentiated and accessible medicines to address unmet medical needs mainly in the US.

Horizon Pharma is a specialty and generic drug manufacturing company. The company is focused on the identification, development, acquisition, and commercialization of differentiated and accessible medicines that address unmet medical needs. The overwhelming majority of revenue is generated in the United States. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Top Ranked Articles about Horizon Pharma PLC

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Officer
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference
Horizon Pharma plc Appoints Pascale Witz and James Shannon, M.D. to Board of Directors
Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and for the Chronic Granulomatous Disease (CGD) Community
Horizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family Conference
Horizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017
Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartrate) delayed-release capsules and QUINSAIR™ (levofloxacin nebuliser solution) in Europe, Middle East and Africa (EMEA) Regions to Chiesi Farmaceutici S
Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotechnology Innovation Organization (BIO) International Convention

Ratios

vs
industry
vs
history
Forward PE Ratio 11.10
HZNP's Forward PE Ratio is ranked higher than
81% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. HZNP: 11.10 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.96
HZNP's PB Ratio is ranked higher than
75% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. HZNP: 1.96 )
Ranked among companies with meaningful PB Ratio only.
HZNP' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 2.16 Max: 14.94
Current: 1.96
0.8
14.94
PS Ratio 1.94
HZNP's PS Ratio is ranked higher than
63% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. HZNP: 1.94 )
Ranked among companies with meaningful PS Ratio only.
HZNP' s PS Ratio Range Over the Past 10 Years
Min: 1.47  Med: 4.12 Max: 19
Current: 1.94
1.47
19
Price-to-Free-Cash-Flow 5.97
HZNP's Price-to-Free-Cash-Flow is ranked higher than
93% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. HZNP: 5.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HZNP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 9.42 Max: 433
Current: 5.97
5.02
433
Price-to-Operating-Cash-Flow 5.87
HZNP's Price-to-Operating-Cash-Flow is ranked higher than
90% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. HZNP: 5.87 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HZNP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.9  Med: 8.94 Max: 209.52
Current: 5.87
4.9
209.52
EV-to-EBIT -7.57
HZNP's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. HZNP: -7.57 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.9 Max: 219.8
Current: -7.57
-775.4
219.8
EV-to-EBITDA -18.65
HZNP's EV-to-EBITDA is ranked lower than
97% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. HZNP: -18.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.5 Max: 518
Current: -18.65
-608
518
EV-to-Revenue 3.26
HZNP's EV-to-Revenue is ranked higher than
50% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. HZNP: 3.26 )
Ranked among companies with meaningful EV-to-Revenue only.
HZNP' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 5.2 Max: 30.2
Current: 3.26
0.5
30.2
Current Ratio 1.61
HZNP's Current Ratio is ranked lower than
67% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. HZNP: 1.61 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.94 Max: 4.39
Current: 1.61
0.16
4.39
Quick Ratio 1.46
HZNP's Quick Ratio is ranked lower than
60% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. HZNP: 1.46 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.65 Max: 4.27
Current: 1.46
0.16
4.27
Days Inventory 108.47
HZNP's Days Inventory is ranked lower than
57% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. HZNP: 108.47 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 59.25 Max: 184.95
Current: 108.47
13.1
184.95
Days Sales Outstanding 138.58
HZNP's Days Sales Outstanding is ranked lower than
85% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. HZNP: 138.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.08  Med: 90.85 Max: 138.58
Current: 138.58
67.08
138.58
Days Payable 59.28
HZNP's Days Payable is ranked lower than
51% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. HZNP: 59.28 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 27.59  Med: 183.99 Max: 410.36
Current: 59.28
27.59
410.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.70
HZNP's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. HZNP: -34.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HZNP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -428.1  Med: -61.1 Max: 0
Current: -34.7
-428.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.02
HZNP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. HZNP: 1.02 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HZNP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 2.83 Max: 29.51
Current: 1.02
0.97
29.51
Price-to-Median-PS-Value 0.47
HZNP's Price-to-Median-PS-Value is ranked higher than
93% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. HZNP: 0.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HZNP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.02 Max: 4.12
Current: 0.47
0.42
4.12
Earnings Yield (Greenblatt) % -13.21
HZNP's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HZNP: -13.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HZNP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1744.4  Med: -5.55 Max: 2.6
Current: -13.21
-1744.4
2.6

More Statistics

Revenue (TTM) (Mil) $1,029.42
EPS (TTM) $ -2.70
Beta0.57
Short Percentage of Float12.37%
52-Week Range $9.45 - 21.98
Shares Outstanding (Mil)163.35

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,047 1,101 1,177
EPS ($) 1.00 1.11 1.60
EPS without NRI ($) 1.00 1.11 1.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Sep 13 2017 
Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources Offic Sep 11 2017 
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Sep 05 2017 
Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference Aug 24 2017 
Horizon Pharma plc Appoints Pascale Witz and James Shannon, M.D. to Board of Directors Aug 03 2017 
Horizon Pharma plc Launches CGD Connections™ to Deliver Support and Resources Created by and fo Jul 25 2017 
Horizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) D Jul 14 2017 
Horizon Pharma plc to Host Second-Quarter 2017 Conference Call and Webcast on Aug. 7, 2017 Jul 10 2017 
Horizon Pharma plc Completes Sale of European Marketing Rights for PROCYSBI® (cysteamine bitartra Jun 23 2017 
Horizon Pharma plc Partners with Global Genes® to Unite the Rare Disease Community at the Biotech Jun 20 2017 

More From Other Websites
Is Horizon Pharma (HZNP) A Suitable Pick for Value Investors? Sep 21 2017
IIROC Trade Halt - Horizon Petroleum Ltd. Sep 19 2017
Horizon Pharma weighs sale of primary care unit -sources Sep 15 2017
Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : September 14,... Sep 14 2017
ETFs with exposure to Horizon Pharma Plc : September 13, 2017 Sep 13 2017
Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Sep 13 2017
Horizon Pharma Plc :HZNP-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Sep 11 2017
See what the IHS Markit Score report has to say about Horizon Pharma PLC. Sep 11 2017
Horizon Pharma plc Names Irina Konstantinovsky Executive Vice President, Chief Human Resources... Sep 11 2017
Horizon Pharma plc to Participate in Morgan Stanley 15th Annual Global Healthcare Conference Aug 24 2017
Nuvo Pharmaceuticals™ Secures Credit Facility from the Royal Bank of Canada Aug 24 2017
Horizon Pharma Plc – Value Analysis (NASDAQ:HZNP) : August 21, 2017 Aug 21 2017
Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session Aug 18 2017
Today's Research Reports on Stocks to Watch: TherapeuticsMD Inc. and Horizon Pharma Aug 18 2017
Here's Why Horizon Pharma Gained as Much as 13.1% Today Aug 17 2017
Edited Transcript of HZNP earnings conference call or presentation 7-Aug-17 12:00pm GMT Aug 13 2017
IHS Markit Score upgrades Horizon Pharma PLC to 40 out of 100, despite ranking positively in only... Aug 11 2017
Horizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : August 10,... Aug 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}